Alboctalol is a pharmaceutical compound primarily classified as a beta-adrenergic antagonist, commonly used in the treatment of hypertension and certain cardiac conditions. It exhibits both beta-1 and beta-2 adrenergic blocking properties, which contribute to its effectiveness in reducing heart rate and blood pressure. The compound is characterized by its ability to selectively inhibit the action of catecholamines, such as adrenaline, on the heart and vascular system, leading to decreased cardiac output and peripheral resistance. Alboctalol also possesses some intrinsic sympathomimetic activity, which means it can partially stimulate beta receptors while blocking them, providing a unique profile compared to other beta-blockers. Its pharmacokinetics involve oral administration, with metabolism primarily occurring in the liver. The compound is generally well-tolerated, but like other beta-blockers, it may have side effects such as fatigue, dizziness, or gastrointestinal disturbances. Overall, Alboctalol represents a valuable option in the management of cardiovascular diseases, particularly for patients who may benefit from its dual action.

Alboctalol

62394-00-7: Alboctalol is a pharmaceutical compound primarily classified as a beta-adrenergic antagonist, commonly used in the treatment of hypertension and certain cardiac conditions. It exhibits both beta-1 and beta-2 adrenergic blocking properties, which contribute to its effectiveness in reducing heart rate and blood pressure. The compound is characterized by its ability to selectively inhibit the action of catecholamines, such as adrenaline, on the heart and vascular system, leading to decreased cardiac output and peripheral resistance. Alboctalol also possesses some intrinsic sympathomimetic activity, which means it can partially stimulate beta receptors while blocking them, providing a unique profile compared to other beta-blockers. Its pharmacokinetics involve oral administration, with metabolism primarily occurring in the liver. The compound is generally well-tolerated, but like other beta-blockers, it may have side effects such as fatigue, dizziness, or gastrointestinal disturbances. Overall, Alboctalol represents a valuable option in the management of cardiovascular diseases, particularly for patients who may benefit from its dual action.

Alboctalol inhibits mushroom tyrosinase activity.

CAS 62394-00-7

Alboctalol

Alboctalol

Ref: TM-TN3372

Alboctalol

Ref: BP-SBP00281